Human dehydroepiandrosterone sulfotransferase pharmacogenetics

Quantitative Western analysis and gene sequence polymorphisms

Thomas C. Wood, Chengtao Her, Ibrahim Aksoy, Diane M. Otterness, Richard M Weinshilboum

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Dehydroepiandrosterone sulfotransferase (DHEA ST) catalyzes the sulfation of DHEA and other hydroxysteroids. DHEA ST enzymatic activity in individual human liver biopsy samples has been shown to vary over a five-fold range, and frequency distribution histograms are bimodal, with approximately 25% of subjects included in a high activity subgroup. We set out to characterize the molecular basis for variation in human liver DHEA ST activity. The first step involved performing quantitative Western analysis of cytosol preparations from 92 human liver samples that had been phenotyped with regard to level of DHEA ST enzymatic activity. There was a highly significant correlation (r(s) = 0.635, P < 0.0001) between levels of DHEA ST activity and immunoreactive protein. We next attempted to determine whether the expression of DHEA ST might be controlled, in part, by a genetic polymorphism. DNA was isolated from three 'low' and three 'high' DHEA ST activity liver samples. Exons and the 5'-flanking region of the DHEA ST gene (STD) were amplified for each of these samples with the polymerase chain reaction (PCR). When compared with ('wild type' STD sequence, some of the samples contained a T→C transition at DHEA ST cDNA nucleotide 170, located within exon 2, resulting in a Met 57→Thr change in amino acid. Other samples contained an A→T transversion at nucleotide 557 within STD exon 4 that resulted in a Glu 186→Val change. STD exons 2 and 4 were then sequenced for DNA isolated from an additional 87 liver samples that had been phenotyped with regard to level of DHEA ST enzymatic activity. The allele frequency for the exon 2 polymorphism in these samples was 0.027, whereas that for the exon 4 polymorphism was 0.038, but neither polymorphism was systematically related to the level of enzyme activity in these samples. Transient expression in COS-1 cells of cDNA that contained the nucleotide 170 and 557 polymorphisms, either separately or together, resulted in decreased expression of both DHEA ST enzymatic activity and level of immunoreactive protein, but only when the nucleotide 557 variant was present. Identification of common genetic polymorphisms within STD will now make it possible to test the hypothesis that those polymorphisms might alter in vivo expression and/or function of this important human steroid-metabolizing enzyme.

Original languageEnglish (US)
Pages (from-to)467-478
Number of pages12
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume59
Issue number5-6
DOIs
StatePublished - Dec 1996

Fingerprint

Pharmacogenetics
Polymorphism
Sequence Analysis
Genes
Chemical analysis
Sexually Transmitted Diseases
Exons
Liver
Nucleotides
Genetic Polymorphisms
dehydroepiandrosterone sulfotransferase
Complementary DNA
Hydroxysteroids
Dehydroepiandrosterone
Biopsy
5' Flanking Region
COS Cells
Polymerase chain reaction
DNA
Enzyme activity

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Human dehydroepiandrosterone sulfotransferase pharmacogenetics : Quantitative Western analysis and gene sequence polymorphisms. / Wood, Thomas C.; Her, Chengtao; Aksoy, Ibrahim; Otterness, Diane M.; Weinshilboum, Richard M.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 59, No. 5-6, 12.1996, p. 467-478.

Research output: Contribution to journalArticle

@article{52522738d57d489b8ffa26b82e9a9533,
title = "Human dehydroepiandrosterone sulfotransferase pharmacogenetics: Quantitative Western analysis and gene sequence polymorphisms",
abstract = "Dehydroepiandrosterone sulfotransferase (DHEA ST) catalyzes the sulfation of DHEA and other hydroxysteroids. DHEA ST enzymatic activity in individual human liver biopsy samples has been shown to vary over a five-fold range, and frequency distribution histograms are bimodal, with approximately 25{\%} of subjects included in a high activity subgroup. We set out to characterize the molecular basis for variation in human liver DHEA ST activity. The first step involved performing quantitative Western analysis of cytosol preparations from 92 human liver samples that had been phenotyped with regard to level of DHEA ST enzymatic activity. There was a highly significant correlation (r(s) = 0.635, P < 0.0001) between levels of DHEA ST activity and immunoreactive protein. We next attempted to determine whether the expression of DHEA ST might be controlled, in part, by a genetic polymorphism. DNA was isolated from three 'low' and three 'high' DHEA ST activity liver samples. Exons and the 5'-flanking region of the DHEA ST gene (STD) were amplified for each of these samples with the polymerase chain reaction (PCR). When compared with ('wild type' STD sequence, some of the samples contained a T→C transition at DHEA ST cDNA nucleotide 170, located within exon 2, resulting in a Met 57→Thr change in amino acid. Other samples contained an A→T transversion at nucleotide 557 within STD exon 4 that resulted in a Glu 186→Val change. STD exons 2 and 4 were then sequenced for DNA isolated from an additional 87 liver samples that had been phenotyped with regard to level of DHEA ST enzymatic activity. The allele frequency for the exon 2 polymorphism in these samples was 0.027, whereas that for the exon 4 polymorphism was 0.038, but neither polymorphism was systematically related to the level of enzyme activity in these samples. Transient expression in COS-1 cells of cDNA that contained the nucleotide 170 and 557 polymorphisms, either separately or together, resulted in decreased expression of both DHEA ST enzymatic activity and level of immunoreactive protein, but only when the nucleotide 557 variant was present. Identification of common genetic polymorphisms within STD will now make it possible to test the hypothesis that those polymorphisms might alter in vivo expression and/or function of this important human steroid-metabolizing enzyme.",
author = "Wood, {Thomas C.} and Chengtao Her and Ibrahim Aksoy and Otterness, {Diane M.} and Weinshilboum, {Richard M}",
year = "1996",
month = "12",
doi = "10.1016/S0960-0760(96)00142-2",
language = "English (US)",
volume = "59",
pages = "467--478",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "5-6",

}

TY - JOUR

T1 - Human dehydroepiandrosterone sulfotransferase pharmacogenetics

T2 - Quantitative Western analysis and gene sequence polymorphisms

AU - Wood, Thomas C.

AU - Her, Chengtao

AU - Aksoy, Ibrahim

AU - Otterness, Diane M.

AU - Weinshilboum, Richard M

PY - 1996/12

Y1 - 1996/12

N2 - Dehydroepiandrosterone sulfotransferase (DHEA ST) catalyzes the sulfation of DHEA and other hydroxysteroids. DHEA ST enzymatic activity in individual human liver biopsy samples has been shown to vary over a five-fold range, and frequency distribution histograms are bimodal, with approximately 25% of subjects included in a high activity subgroup. We set out to characterize the molecular basis for variation in human liver DHEA ST activity. The first step involved performing quantitative Western analysis of cytosol preparations from 92 human liver samples that had been phenotyped with regard to level of DHEA ST enzymatic activity. There was a highly significant correlation (r(s) = 0.635, P < 0.0001) between levels of DHEA ST activity and immunoreactive protein. We next attempted to determine whether the expression of DHEA ST might be controlled, in part, by a genetic polymorphism. DNA was isolated from three 'low' and three 'high' DHEA ST activity liver samples. Exons and the 5'-flanking region of the DHEA ST gene (STD) were amplified for each of these samples with the polymerase chain reaction (PCR). When compared with ('wild type' STD sequence, some of the samples contained a T→C transition at DHEA ST cDNA nucleotide 170, located within exon 2, resulting in a Met 57→Thr change in amino acid. Other samples contained an A→T transversion at nucleotide 557 within STD exon 4 that resulted in a Glu 186→Val change. STD exons 2 and 4 were then sequenced for DNA isolated from an additional 87 liver samples that had been phenotyped with regard to level of DHEA ST enzymatic activity. The allele frequency for the exon 2 polymorphism in these samples was 0.027, whereas that for the exon 4 polymorphism was 0.038, but neither polymorphism was systematically related to the level of enzyme activity in these samples. Transient expression in COS-1 cells of cDNA that contained the nucleotide 170 and 557 polymorphisms, either separately or together, resulted in decreased expression of both DHEA ST enzymatic activity and level of immunoreactive protein, but only when the nucleotide 557 variant was present. Identification of common genetic polymorphisms within STD will now make it possible to test the hypothesis that those polymorphisms might alter in vivo expression and/or function of this important human steroid-metabolizing enzyme.

AB - Dehydroepiandrosterone sulfotransferase (DHEA ST) catalyzes the sulfation of DHEA and other hydroxysteroids. DHEA ST enzymatic activity in individual human liver biopsy samples has been shown to vary over a five-fold range, and frequency distribution histograms are bimodal, with approximately 25% of subjects included in a high activity subgroup. We set out to characterize the molecular basis for variation in human liver DHEA ST activity. The first step involved performing quantitative Western analysis of cytosol preparations from 92 human liver samples that had been phenotyped with regard to level of DHEA ST enzymatic activity. There was a highly significant correlation (r(s) = 0.635, P < 0.0001) between levels of DHEA ST activity and immunoreactive protein. We next attempted to determine whether the expression of DHEA ST might be controlled, in part, by a genetic polymorphism. DNA was isolated from three 'low' and three 'high' DHEA ST activity liver samples. Exons and the 5'-flanking region of the DHEA ST gene (STD) were amplified for each of these samples with the polymerase chain reaction (PCR). When compared with ('wild type' STD sequence, some of the samples contained a T→C transition at DHEA ST cDNA nucleotide 170, located within exon 2, resulting in a Met 57→Thr change in amino acid. Other samples contained an A→T transversion at nucleotide 557 within STD exon 4 that resulted in a Glu 186→Val change. STD exons 2 and 4 were then sequenced for DNA isolated from an additional 87 liver samples that had been phenotyped with regard to level of DHEA ST enzymatic activity. The allele frequency for the exon 2 polymorphism in these samples was 0.027, whereas that for the exon 4 polymorphism was 0.038, but neither polymorphism was systematically related to the level of enzyme activity in these samples. Transient expression in COS-1 cells of cDNA that contained the nucleotide 170 and 557 polymorphisms, either separately or together, resulted in decreased expression of both DHEA ST enzymatic activity and level of immunoreactive protein, but only when the nucleotide 557 variant was present. Identification of common genetic polymorphisms within STD will now make it possible to test the hypothesis that those polymorphisms might alter in vivo expression and/or function of this important human steroid-metabolizing enzyme.

UR - http://www.scopus.com/inward/record.url?scp=0030461435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030461435&partnerID=8YFLogxK

U2 - 10.1016/S0960-0760(96)00142-2

DO - 10.1016/S0960-0760(96)00142-2

M3 - Article

VL - 59

SP - 467

EP - 478

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 5-6

ER -